In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) improves progression-free survival (PFS) relative to a doublet checkpoint inhibitor (CPI) combination of nivolumab (Opdivo, Bristol Myers Squibb [BMS]) and ipilimumab (Yervoy, BMS). The data were presented as a late-breaker (abstract LBA 8) at the 2022 annual meeting of the European Society of Medical Oncology (ESMO).
Although the three-drug combination was less well